Trial Profile
A Phase II Trial of Bortezomib (Velcade) Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2015
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Prednisone
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2012 Planned end date changed from 1 Jan 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 23 Jan 2012 Planned end date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.